Rescue Therapy for Helicobacter Pylori Infection

Launched by SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · May 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying different treatment options for people who have a persistent infection with Helicobacter pylori (H. pylori), a type of bacteria that can cause stomach issues. The researchers want to compare three treatment methods: a dual therapy that includes vonoprazan and amoxicillin, a triple therapy that contains rifabutin, and a quadruple therapy with bismuth. The goal is to find out which of these treatments works best to help patients whose previous H. pylori treatments have not been successful.

To participate in the trial, individuals must be between 18 and 80 years old and have been diagnosed with H. pylori after trying other treatments. They should be willing to sign a consent form to join the study. However, people who have never been treated for H. pylori, have had stomach surgery, are pregnant or breastfeeding, have a history of tuberculosis, or have allergies to the study medications cannot take part. Participants can expect to receive one of the three treatments and will be monitored closely for effectiveness and safety throughout the study. This trial is currently recruiting participants, and the findings could lead to better treatment options for those struggling with H. pylori infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability and willingness to participate in the study and to sign and give informed consent
• • Confirmed H. pylori infection and with previous treatment experience
• Exclusion Criteria:
• • subjects naive to H. pylori treatment,
• • under 18 or over 80 years old
• • history of gastrectomy
• • pregnant or lactating women
• • Previous history of tuberculosis
• • Allergy to any of the study drugs
• • severe systemic diseases or malignancy
• • administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks